Rather than producing medicines through batch-wise, step-by-step processes, CONTINUUS Pharmaceuticals offers a breakthrough Integrated Continuous Manufacturing (ICM) technology for small molecule pharmaceuticals. The synthesis of the active ingredient and the final dosage form are integrated into a seamless process. This novel method will allow “on-demand” manufacturing of pharmaceuticals with significant advantages in production lead time, quality, and costs.
CONTINUUS Pharmaceuticals is a spin-out company of the $65 M collaboration between MIT and Novartis on continuous manufacturing, We design, build, and run our manufacturing processes directly at the client site. This novel business strategy provides our pharmaceutical and generic clients with an exceptional, ”one-shop solution” for their entire development and manufacturing cycle. Our success is based on the establishment of long term partnerships with our clients.
CONTINUUS at the Global Pharma Manufacturing Summit and IFPAC 2014
CONTINUUS closes $2 M Series A Financing and establishes a strategic partnership with I.M.A. Industria Macchine Automatiche
CONTINUUS receives an additional seed investment, taking the company to a total capitalization of $395,000